Related Experiment Video

Updated: Jul 18, 2026

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses
11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

New treatment strategies against hepatitis C viral infection

Marc Bilodeau1, Daniel Lamarre

  • 1Service d'hepatologie, Hopital Saint-Luc du CHUM, Montreal, Canada. Marc.Bilodeau@umontreal.ca

Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|November 18, 2006
PubMed

Insights

New hepatitis C virus treatments are being developed due to suboptimal efficacy and side effects of current therapies. This review examines the rationale and clinical data for these novel hepatitis C treatments.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Current hepatitis C virus (HCV) treatment relies on pegylated interferon and ribavirin.
  • This standard therapy exhibits suboptimal efficacy and can cause problematic side effects.
  • Significant research efforts are underway to develop alternative HCV treatments.

Purpose of the Study:

  • To review the scientific rationale behind the development of new HCV treatments.
  • To present and analyze current clinical efficacy data for emerging HCV therapies.

Main Methods:

  • Literature review of scientific rationale for novel drug development.
  • Analysis of clinical study data presented at major international meetings.
  • Synthesis of information on alternative treatment strategies for chronic HCV infection.

Main Results:

  • Several new classes of antiviral agents are under investigation.
  • Early clinical data suggest varying degrees of efficacy and safety profiles for novel agents.
  • The development landscape for HCV therapeutics is rapidly evolving.

Conclusions:

  • Alternative treatments for hepatitis C virus infection are crucial due to limitations of current therapy.
  • Emerging agents show promise but require further evaluation for widespread clinical use.
  • Continued research and development are essential to improve outcomes for patients with chronic hepatitis C.

More Related Videos

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...